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DOI 10.1186/s12894-017-0226-2RESEARCH ARTICLE Open AccessA retrospective study of treatment
persistence and adherence to α-blocker
plus antimuscarinic combination therapies,
in men with LUTS/BPH in the Netherlands
Marcus J. Drake1* , Sally Bowditch2, Emilio Arbe2, Zalmai Hakimi3, Florent Guelfucci4, Ikbel Amri5
and Jameel Nazir2Abstract
Background: To assess treatment persistence and adherence in men ≥45 years of age with lower urinary tract
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), using prescription records from the Netherlands
IMS Lifelink™ LRx database.
Methods: In this retrospective, observational cohort study, we identified men who received combination therapy with
an α-blocker plus an antimuscarinic (e.g. solifenacin or tolterodine) between 1 November 2013 and 31 October 2014.
Treatment could be received as a fixed-dose combination (FDC) tablet or as two drugs administered together
(concomitant therapy), if both combination drugs were prescribed within 30 days. The primary objective was to
assess treatment persistence, defined as the time from initiation of combination therapy until first discontinuation
of the FDC or at least one of the drugs given concomitantly (i.e. ≥30 days without prescription renewal). Subgroup and
sensitivity analyses were conducted to assess persistence by antimuscarinic agent, and with different gap lengths used
to define discontinuation (45, 60 and 90 days), respectively.
Results: A total of 1891 men received an α-blocker plus an antimuscarinic (FDC, N = 665; concomitant therapy,
N = 1226). Median time to discontinuation was significantly longer with FDC versus concomitant therapy (414 vs.
112 days; adjusted hazard ratio [HR] 2.04, 95% confidence interval 1.77, 2.35; p < 0.0001). Persistence at 12 months (51.3%
vs. 29.9%) was also significantly greater with FDC compared with concomitant therapy. Assessment of antimuscarinic
subgroups showed that median time to discontinuation was longest with solifenacin combinations (214 days) compared
with other antimuscarinic combinations (range, 47–164 days; adjusted HR range, 1.27–1.77, p = 0.037). No observable
impact on treatment persistence was found by adjusting the gaps used to define discontinuation.
Discussion: This study of real-world evidence of men with LUTS/BPH treated with α-blocker plus antimuscarinic
combination therapy in the Netherlands showed that treatment persistence was significantly greater in those who
received a FDC tablet compared with combination therapy given concomitantly. The study also shows that treatment
persistence was extended in men who received combination therapy containing solifenacin compared with other
antimuscarinics.
Conclusions: Overall, these findings may be useful for prescribers, as improved persistence on-treatment may translate
into improved outcomes for men with LUTS/BPH. Further study is warranted to establish the key drivers of persistence in
men receiving combination therapy for LUTS/BPH.
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Lower urinary tract symptoms (LUTS) are most com-
mon in the ageing male population, with troublesome
LUTS occurring in 30% of men over 65 years of age [1].
LUTS can be divided into voiding, storage and post-
micturition symptoms [2]. Although the treatment of
LUTS tends to focus on voiding symptoms [1, 2], men
typically report storage symptoms (e.g. increased fre-
quency, urgency and nocturia [1, 2]) as the most bother-
some [3, 4].
LUTS are commonly associated with benign prostatic
hyperplasia (BPH), i.e. LUTS/BPH [1]; together, these con-
ditions have been shown to have a significant impact on
men’s health-related quality of life and daily activities [5].
Current European recommendations for treatment of
LUTS include the use of lifestyle interventions, and
pharmacological therapies when these interventions are
inappropriate or unsuccessful (i.e. in men with moderate-
to-severe LUTS) [2]. Pharmacological treatment options
include α-blockers, antimuscarinics and 5α-reductase
inhibitors (5-ARIs), which can either be used as monother-
apy or in combination, and recent evidence suggests that
the use of pharmacological treatments for LUTS/BPH is
increasing in some healthcare systems, particularly as
combination therapy [6]. The European recommendations
suggest different indications for combination therapy,
i.e. α-blocker plus an antimuscarinic if relief of storage
symptoms has been insufficient with monotherapy of
either drug; and α-blocker plus a 5-ARI in men with a
substantially enlarged prostate (those more likely to
experience disease progression) [2].
Combination therapies can be administered separately
(i.e. as concomitant therapy), or as a fixed-dose combin-
ation (FDC) in a single tablet. Several randomised,
double-blinded trials conducted in men >40 years of age
with LUTS/BPH and overactive bladder (OAB) symp-
toms have demonstrated improved efficacy in those who
received α-blocker plus antimuscarinic combination
therapy concomitantly compared with monotherapy [7–
10]. With regards to FDCs, a randomised, double-blind,
multicentre, phase III study of 1690 men ≥45 years of
age with moderate-to-severe LUTS/BPH (NEPTUNE;
Clinicaltrials.gov identifier: NCT01018511), demon-
strated that a FDC of solifenacin 6 mg plus tamsulosin
oral controlled absorption system (TOCAS, 0.4 mg) sig-
nificantly improved voiding and storage symptoms ver-
sus placebo, and storage symptoms versus TOCAS alone
[11]. The FDC tablet of solifenacin 6 mg plus TOCAS is
approved for the treatment of men with moderate-to-
severe LUTS/BPH in Europe [12] and was first
authorised for marketing in the Netherlands in May
2013 [13]. A FDC of dutasteride and tamsulosin is ap-
proved for use in Europe, but only for men with LUTS
and an enlarged prostate [14].Despite the improvements in symptoms of LUTS/
BPH, treatment persistence (i.e. the duration from initi-
ation to discontinuation of therapy [15]) and adherence
(i.e. the extent to which a patient acts in accordance
with the prescribed interval, and dose of a dosing regi-
men [15]) are reported to be low in men with LUTS/
BPH. An observational study of 8694 men ≥45 years of
age with LUTS/BPH conducted in the United Kingdom
(UK) showed that 38.5% and 53.0% of men discontinued
α-blocker and antimuscarinic therapy, respectively, over
a median duration of 2.1 years’ treatment [16]; and a
retrospective study of 670 men with LUTS/BPH in
Korea found that approximately two-thirds of men dis-
continued an α-blocker, a 5-ARI, or both treatments in
combination within 1 year of starting treatment) [17]. In
the latter study, adverse events (AEs) were among the
most common reasons for discontinuation and for
switching of treatment.
Overall, there are limited published data regarding
treatment patterns in men receiving combination ther-
apy for LUTS/BPH in routine clinical practice. The aims
of this study were to assess treatment persistence and
adherence with α-blocker plus antimuscarinic combin-
ation therapy in men with LUTS/BPH, and compare
these endpoints with treatment administered either as a
FDC or combination therapy given concomitantly.
Methods
Study design
This was a retrospective, observational cohort study of
men with LUTS/BPH who received prescription(s) for
combination therapy with an α-blocker plus an antimus-
carinic or a 5-ARI. Anonymised patient longitudinal pre-
scription records and demographic data were extracted
from the Netherlands IMS LifeLink™ LRx database,
which consists of data from pharmacies and dispensing
general practitioners (GPs) in the Netherlands (total
sample is representative of around 16.5 million people).
The primary objective of the study was to assess treat-
ment persistence in men who received α-blocker plus
antimuscarinic combination therapy when prescribed as
a FDC, compared with prescriptions of separate combin-
ation drugs (concomitant therapy). Adherence was also
assessed in these two comparative groups as a secondary
objective. Other secondary objectives included: compar-
ing treatment persistence with an α-blocker plus an anti-
muscarinic combination therapy in subgroups defined
by the antimuscarinic drug prescribed; and determining
the impact of patient/clinical characteristics associated
with persistence to combination therapy. Exploratory
objectives were to determine the proportion of men who
switched combination therapy (described below); and
to compare treatment persistence and adherence in
men prescribed with any FDC versus any concomitant
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both types).Study population
Men ≥45 years of age were treated with combination
therapy of an α-blocker plus an antimuscarinic or
5-ARI, prescribed either as a FDC or concomitantly
(see Additional file 1: Table S1 for eligible drugs).
Combination therapy had to be first prescribed
between 1 November 2013 and 31 October 2014 (i.e.
the selection period) (Additional file 2: Figure S1),
prescriptions had to be received on the same day or
within a 30-day window, and all men required continuous
enrolment 6 months prior to and 12 months after the start
of receiving combination therapy. The end date of
database interrogation was 31 October 2015. The start or
index date was defined as the date of first prescription of
combination therapy – if combination drugs were not
received on the same day, the index date was the day on
which the second drug in combination was first
prescribed. Men were excluded if they received only
monotherapy for an eligible drug within the selection
period or if they were prescribed the same combination
therapy on and prior to the index date.Endpoints
Treatment persistence (primary endpoint) was defined
here as the time from the index date until first discon-
tinuation of at least one of the index combination drugs.
The median time to discontinuation, and the proportion
of men persistent at 12-months were reported. An index
drug was considered discontinued after a period of
≥30 days without prescription renewal; the date of dis-
continuation was the date of the last prescription of the
first discontinued drug in the combination, plus the days
of supply of that prescription.
Adherence (secondary endpoint), defined as medical
possession ratio (MPR, i.e. the period in which patients
have treatment in their possession), was calculated by
two methods: the sum of days of supply of the index
combination therapy divided by the time to discontinu-
ation (MPR variable) or the sum of days of supply of the
index combination therapy divided by 365 days (MPR
fixed). The MPR was calculated as mean or median;
men were considered as adherent if an MPR of ≥80%
was achieved.
Treatment switching (exploratory endpoint), defined
as the proportion of men who switched from index com-
bination therapy to another combination therapy (i.e. if
at least one drug in the index combination drugs was
discontinued and replaced with at least one new drug
after the last prescription date, within the 30 days fol-
lowing the discontinuation date).Statistical analyses
The main analysis was performed in all men who re-
ceived an α-blocker plus antimuscarinic, either as FDC
or as concomitant therapy. Comparisons of persistence
and adherence in this population were performed for
FDC α-blocker plus an antimuscarinic compared with
concomitant α-blocker plus an antimuscarinic; and
α-blocker plus antimuscarinic combination therapy
defined by the antimuscarinic agent. An exploratory
analysis was performed in men who received any FDC
therapy versus any concomitant therapy (α-blocker plus
antimuscarinic or 5-ARI in both groups).
Baseline demographics and characteristics were reported
descriptively. Time to discontinuation was presented using
Kaplan-Meier curves. Treatment persistence and adherence
were assessed using multivariate Cox regression models
that adjusted for potential confounding factors at index
date: age, polypharmacy (number of Anatomical
Therapeutic Chemical [ATC3] class drugs [defined by the
European Pharmaceutical Market Research Association]
excluding those approved for the treatment of LUTS/BPH),
and type of prescriber. Adjusted hazard ratios (HRs) with
associated confidence intervals (CIs) and p-values are
reported for comparisons of FDC and concomitant therapy;
the FDC was used as the reference. Linear regression
models were used for associations of potential confounding
factors with MPR.
Several sensitivity analyses of time to discontinuation
were performed. One analysis on the definition of time
to discontinuation increased the period without pre-
scription renewal from 30 days to 45, 60 and 90 days in
the base-case cohort of men (i.e. those who initiated
α-blocker and antimuscarinic combination therapy
within a 30 day window). Other analyses of time to
discontinuation (defined by 30 days without prescription
renewal) were performed in men who were treatment-
naïve for combination treatment during the pre-index
period; men who first received prescriptions for α-blocker
and antimuscarinic combination therapy on the same date;
and men who first received prescriptions for α-blocker and
antimuscarinic combination therapy within an extended
60 day window.
Results
Baseline demographics and characteristics
In total, 377,155 patients were prescribed with a target
drug for LUTS/BPH treatment between 1 November
2013 and 31 October 2014. Overall, 371,560 patients
were excluded (the most common reason for exclusion
was the absence of prescription of an α-blocker and an
antimuscarinic or 5-ARI within 30 days of each other
during the study period [N = 313,669]), leaving a final
study population of 5595 eligible men (Fig. 1). Of these,
1891 men received an α-blocker plus an antimuscarinic
Total patients excluded: N = 371,560 (98.5%)* 
Women
Patients <45 years of age at index date
Patients without -blocker and antimuscarinic or 5-ARI prescriptions within
30 days of each other, during the study period
Patients with continuous 6-month follow-up before index date‡
Patients without continuous 12-month follow-up after index date‡
Patients with prescription of the same combination therapy during the
pre-index period
Source cohort
Patients with a prescription for target LUTS/BPH treatment
between 1 November 2013 and 31 October 2014
N = 377,155
Study cohort
Eligibile men 45 years of age with targeted combination
treatment for LUTS/BPH during selection period
N = 5595 (1.48%)
FDC -blocker and antimuscarinic
Concomitant -blocker and antimuscarinic
FDC -blocker and 5-ARI
Concomitant -blocker and 5-ARI
Other§
N = 665 (11.9%)
N = 1226 (21.9%)
N = 1743 (31.2%)
N = 1262 (22.6%)
N = 699 (12.5%)
N = 77,282 (20.5%)
N = 27,323 (7.2%)
N = 313,669 (83.2%)
N = 131,421 (34.8%)
N = 179,067 (47.5%)
N = 36,967 (9.8%)
Fig. 1 Patient selection flowchart. *Patients excluded by exclusion/inclusion criterion, applied independently from each other; ‡A continuous
follow-up period was confirmed by the dispensation of any medication 6 months prior to the index date and 12 months following the index
date, with no gap in pharmacy records; §Patients with more than two drugs prescribed within 30 days of each other. 5-ARI: 5α-reductase inhibitor;
FDC: fixed-dose combination; LUTS/BPH: lower urinary tract symptoms associated with benign prostatic hyperplasia
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receiving an α-blocker plus an antimuscarinic combin-
ation, the most common antimuscarinic was solifenacin
(N = 1407) and flavoxate the least common (N = 23).
Baseline characteristics in the cohort that received an
α-blocker plus an antimuscarinic are shown in Table 1.
The mean age at index date was 71.95 years and a high
proportion of men received α-blocker monotherapy
(88.2%) and/or antimuscarinic monotherapy (52.3%) prior
to the index date. Baseline characteristics were generally
similar when comparing men who received either a FDC
or concomitant therapy of an α-blocker plus an antimus-
carinic. However, a higher proportion of men prescribed
with a FDC compared with the concomitant therapy
group had received ≤3 different drug classes for conditions
other than LUTS/BPH at baseline (74.7% vs. 53.2%); were
prescribed combination therapy at index date by a
urologist (68.6% vs. 22.0%); and had received any prior
combination therapy (34.6% vs. 20.3%) or 5-ARI
monotherapy (13.2 vs. 5.6%). Overall, baseline characteris-
tics were similar in subgroups based on the prescribed
antimuscarinic at index date (Additional file 3: Table S2).
α-blocker plus antimuscarinic: FDC versus concomitant
therapy
Overall time to discontinuation
Median time to discontinuation was significantly longer
with α-blocker plus antimuscarinic FDC versus concomi-
tant therapy (414 vs. 112 days; adjusted HR 2.04, 95% CI
1.77, 2.35; p < 0.0001) (Fig. 2) and the proportion of menpersistent at 12 months was higher with FDC compared
with concomitant therapy (51.3% vs. 29.9%).
Impact of patient/clinical characteristics on time to
discontinuation
Median time to discontinuation and persistence at
12 months were greatest in men aged 45–64 years
(217 days and 40.3%) compared with those aged 65–
74 years (189 days and 38.5%) and ≥75 years (150 days and
35.1%), although the differences were not statistically sig-
nificant (Fig. 3). When the results were stratified by the
number of drugs received at index date, no significant pat-
terns were observed for median time to discontinuation
(range, 153–207 days) and persistence at 12 months
(range, 34.0%–40.3%) (Fig. 3; Additional file 4: Table S3).
Similarly, no significant differences were observed for
median time to discontinuation and persistence at
12 months in men prescribed by a urologist (234 days and
41.5%) compared with those prescribed by a GP (148 days
and 35.1%; adjusted HR 0.89, 95% CI 0.78, 1.02; p = 0.095)
or those prescribed by other healthcare providers (181 days
and 34.2%; adjusted HR 1.00, 95% CI 0.83, 1.20; p = 0.976).
Adherence
Mean MPR and the proportion of men adherent at
12 months were similar for men who received FDC and
concomitant therapy (Table 2). Similar adherence data in
the FDC and concomitant therapy groups were also evi-
dent in the subgroup of men who were persistent at
12 months.
Table 1 Baseline characteristicsa in those receiving combination therapy with an α-blocker plus an antimuscarinic
Overall population
(N = 1891)b
FDC
(N = 665)
Concomitant therapy
(N = 1226)
Age at index date, mean (SD) 71.95 (9.55) 70.46 (9.11) 72.77 (9.68)
Age at index date, N (%)
45–64 years 417 (22.1) 172 (25.9) 245 (20.0)
65–74 years 654 (34.6) 260 (39.1) 394 (32.1)
≥75 years 820 (43.4) 233 (35.0) 587 (47.9)
Polypharmacy,c mean (SD) 3.38 (3.33) 4.35 (3.18) 5.54 (3.40)
Polypharmacy,c N (%)
0 420 (22.2) 223 (33.5) 197 (16.1)
1–3 729 (38.6) 274 (41.2) 455 (37.1)
4–5 303 (16.0) 79 (11.9) 224 (18.3)
6–8 278 (14.7) 68 (10.2) 210 (17.1)
≥9 161 (8.5) 21 (3.2) 140 (11.4)
Prescriber at index date, N (%)
Urologist 726 (38.4) 456 (68.6) 270 (22.0)
GP 931 (49.2) 130 (19.6) 801 (65.3)
Other 234 (12.4) 79 (11.9) 155 (12.6)
Prior treatment, N (%)
Any combination 479 (25.3) 230 (34.6) 249 (20.3)
α-blocker + antimuscarinic 298 (15.8) 121 (18.2) 177 (14.4)
α-blocker 1668 (88.2) 549 (82.6) 1119 (91.3)
Antimuscarinic 989 (52.3) 237 (35.6) 752 (61.3)
5-ARI 157 (8.3) 88 (13.2) 69 (5.6)
Concomitant therapy, N (%)
Both drugs initiated on the same date – – 341 (27.8)
Both drugs initiated within 30 days – – 885 (72.2)
5-ARI 5α-reductase inhibitor, FDC fixed-dose combination, GP general practitioner, SD standard deviation
aAt index date
bThe overall population comprised men receiving FDC or concomitant therapy of an α-blocker and an antimuscarinic
cNumber of drugs (classified by Anatomical Therapeutic Chemical code) prescribed, excluding those approved for the treatment of LUTS/BPH.
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Compared with the base-case analysis of 30 days, adjust-
ing the time used to define discontinuation of combin-
ation therapy to 45, 60 and 90 days had minimal impact
on the results for concomitant therapy but increased
median time to discontinuation for the FDC (Additional
file 5: Table S4). At each of these timepoints, median
time to discontinuation and persistence at 12 months
were significantly greater in men who received FDC
compared with concomitant therapy (p < 0.001 for all
assessments). In treatment-naïve men, median time to
discontinuation (384 vs. 113 days) and persistence at
12 months (49.6% vs. 30.9%) were significantly greater in
those who received FDC versus concomitant therapy
(adjusted HR 1.83, 95% CI 1.60, 2.09; p < 0.0001) (Add-
itional file 6: Figure S2a). Median time to discontinuation
(414 vs. 198 days) and persistence at 12 months (51.3% vs.
38.7%) were also significantly greater in the FDC groupcompared with men prescribed concomitant combination
treatment on the same day (adjusted HR 1.46, 95% CI
1.23, 1.72; p < 0.0001) (Additional file 6: Figure S2b).
Similarly, in men who received prescriptions for α-blocker
and antimuscarinic combination therapy within a 60 day
window, median time to discontinuation (424 vs. 90 days)
and persistence at 12 months (52.2% vs. 25.7%) were
significantly greater in those who received FDC versus
concomitant therapy (adjusted HR 2.17; 95% CI 1.90, 2.48;
p < 0.0001) (Additional file 6: Figure S2c).
Switching
Among the 1183 men who were non-persistent at
12 months, a similar proportion of men who received
FDC therapy of an α-blocker plus antimuscarinic
switched treatment at 12 months, compared with those
receiving concomitant therapy (5.9% vs. 6.5%, respect-
ively) (Table 3), with the majority of men discontinuing
Treatment duration (days)
Adjusted HR: 2.04
(95% CI 1.77, 2.35); p < 0.0001
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Fig. 2. Median time to discontinuation for FDC versus concomitant therapy α-blocker plus antimuscarinic. CI: confidence intervals; FDC: fixed-dose
combination; HR: hazard ratio; TTD: time to discontinuation
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combination within 30 days. Due to the low number of
men who switched treatment, no clear patterns were ob-
served for the type of treatment men subsequently
switched to.
α-blocker plus antimuscarinic: antimuscarinic drug
subgroups
Overall time to discontinuation
Median time to discontinuation was significantly
longer with FDC or concomitant combinationP
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Polypharmacy‡a
Fig. 3 Median time to discontinuation according to polypharmacy‡ (a) and
plus antimuscarinic combination therapy (FDC or concomitant therapy). ‡N
prescribed, excluding those approved for the treatment of LUTS/BPH. FDC:
associated with benign prostatic hyperplasiatherapies containing an α-blocker plus solifenacin
(214 days), compared with other α-blocker plus anti-
muscarinic combination therapies (range, 47–164 days;
adjusted HR range 1.27–1.77, p = 0.037) (Fig. 4a).
Similarly, the proportion of men persistent at 12 months
was higher with FDC or concomitant combination
therapies containing an α-blocker plus solifenacin
(40.7%) compared with other α-blocker plus
antimuscarinic combinations (range, 24.6%–31.4%).
In the subgroup of men who received an α-blocker
plus solifenacin, median time to discontinuation0 50 100 150 200 250 300 350 400 450 500 550
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fixed-dose combination; LUTS/BPH: lower urinary tract symptoms
Table 2 Adherence in men receiving FDC and concomitant
therapy with an α-blocker plus an antimuscarinic
FDC
α-blocker and
antimuscarinic
Concomitant therapy
α-blocker antimuscarinic
MPR-fixed
N 566 726 726
Mean (SD) 0.91 (0.52) 0.95 (0.37) 0.89 (0.31)
Adherent,a n (%) 453 (80.0) 623 (85.8) 546 (75.2)
MPR-variable
N 566 726 726
Mean (SD) 0.67 (0.31) 0.69 (0.34) 0.64 (0.32)
Adherent,a n (%) 275 (48.6) 358 (49.3) 319 (43.9)
MPR-fixed (persistent men only)
N 313 380 380
Mean (SD) 0.83 (0.21) 0.93 (0.22) 0.85 (0.22)
Adherent,a n (%) 235 (75.1) 324 (85.3) 282 (74.2)
FDC fixed-dose combination, MPRmedical possession ratio, SD standard
deviation
aMPR of ≥80%
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2.26; p < 0.0001) and persistence at 12 months
(51.3% vs. 31.1%) were significantly greater in those
treated with FDC compared with concomitant ther-
apy (Fig. 4b).Table 3 Change of treatment in men initially prescribed an
α-blocker plus an antimuscarinic combination treatment and
non-persistent at 12 months
FDC Concomitant
therapy
Change of treatment in men non-persistent
at 12 months, N (%)
N = 324 N = 859
Switcha 19 (5.9) 56 (6.5)
No switch/discontinuationb 305 (94.1) 803 (93.5)
Switched to, N (%) N = 19 N = 56
Combination with new α-blocker 1 (5.3) 5 (8.9)
Combination with new antimuscarinic 6 (31.6) 25 (44.6)
Concomitant therapy with the same
drugs
9 (47.4) 3 (5.4)
Concomitant therapy with a new
α-blocker and antimuscarinic
3 (15.8) 0
FDC 0 23 (41.1)
No switch/discontinuation, N (%) N = 305 N = 803
α-blocker therapy only 58 (19.0) 246 (30.6)
Antimuscarinic therapy only 19 (6.2) 107 (13.3)
No therapy changes 228 (74.8) 450 (56.0)
FDC fixed-dose combination
aAlternative combination therapy prescribed within 30 days following
discontinuation of index combination therapy
bNo alternative combination therapy prescribed within 30 days following
discontinuation of index combination therapySwitching
Among the 75 men who switched treatment, a similar
proportion of men switched from solifenacin compared
with other antimuscarinics (6.9% vs. range, 2.8–6.1%).
α-blocker plus antimuscarinic or 5-ARI: FDC versus
concomitant therapy
Overall time to discontinuation
A similar number of men received any FDC (N = 2408)
or any concomitant therapy (N = 2488). The median
time to discontinuation was significantly longer in men
who received any FDC versus any concomitant combin-
ation treatment (not reached vs. 193 days; adjusted HR
2.28, 95% CI 2.10, 2.48; p < 0.0001) (Additional file 7:
Figure S3); persistence at 12 months was also greater
(62.1% vs. 38.1%) in the FDC group.
Discussion
This retrospective study assessed treatment persist-
ence and adherence in over 5000 men with LUTS/
BPH and was the first comparison in this population
of men receiving treatment with an α-blocker and an
antimuscarinic, either as a FDC or as concomitant
therapy. Overall, treatment persistence was signifi-
cantly greater in men who received an α-blocker plus
an antimuscarinic as a FDC tablet compared with an
α-blocker plus an antimuscarinic given concomi-
tantly. Treatment adherence (assessed by MPR-fixed
and -variable) was similar in men who received FDC
α-blocker plus antimuscarinic compared with
concomitant therapy.
The main study results of improved treatment per-
sistence with FDC α-blocker plus antimuscarinic com-
pared with concomitant therapy were also observed in
the sensitivity analyses, which tested adjusting the
gaps used to define time to discontinuation. Similar
findings were also observed in the subpopulations of
treatment-naïve men, those prescribed concomitant
combination treatment on the same day, and men
who initiated α-blocker and antimuscarinic combin-
ation therapy within a 60 day window. Overall, these
findings were similar to the base-case analysis and
the HRs reported were stable, suggesting that the
study results are robust.
The foundation of superior treatment persistence
with FDC α-blocker plus antimuscarinic observed in
this study is likely to be multifactorial. The results may
be partly attributable to the convenience of taking a
single tablet (i.e. the FDC) compared with taking two
tablets concomitantly. Indeed, patients receiving anti-
hypertensive FDC therapy compared with concomitant
therapy have reported significantly increased persist-
ence and adherence in a large, retrospective cohort
analysis [18]. In contrast, results from a recent
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ducted using prescription records and hospital dis-
charge codes from ~1.5 million men with LUTS/BPH
in Italy showed that men were significantly less adher-
ent to, and more likely to discontinue treatment with
combination therapy of an α-blocker plus a 5-ARI,
compared with monotherapy with either treatment,
over 5-years of follow-up [19]. However, there are sev-
eral notable differences to the current study: Cindolo
et al. assessed different drug classes (α-blockers and
5-ARIs), defined discontinuation as no prescriptions
for at least two consecutive months, and comparisons
were made between combination therapy and the two
monotherapies, rather than between FDC and concomi-
tant therapies. In the current study, approximately 40% of
the men eligible for inclusion were receiving six or more
other drugs types at index date and therefore it is difficult
to make conclusions about the impact of convenience
from a single tablet on the overall results.Although the efficacy/tolerability of a FDC has not
been directly compared with concomitant combination
treatment for LUTS/BPH, studies in other indications
have reported improved efficacy and tolerability with
FDCs compared with concomitant therapies [20, 21].
The efficacy of FDC therapy in male LUTS has been
shown in several studies, for instance, significant im-
provements in Total Urgency and Frequency Score
(TUFS) was observed for FDC solifenacin 6 mg plus
TOCAS versus TOCAS alone (p = 0.025) in the NEP-
TUNE study of 1334 men with storage and voiding
LUTS/BPH [11]. In this study, no improvements in effi-
cacy were observed when comparing the FDC solifena-
cin 6 mg plus TOCAS versus FDC solifenacin 9 mg
plus TOCAS. However, our study did not account for
different dose strengths or formulations of antimuscari-
nics used in combination, therefore similar conclusions
cannot be drawn with regards to persistence or adher-
ence. An open-label extension of the NEPTUNE trial
Drake et al. BMC Urology  (2017) 17:36 Page 9 of 12(NEPTUNE II) demonstrated that FDC solifenacin
6 mg plus TOCAS was well tolerated (most AEs were
mild or moderate) and reductions in International
Prostate Symptom Score (IPSS) and TUFS were main-
tained for up to 52 weeks [22]. In addition, the results
from a randomised, open-label, 24-month parallel-
group study of 742 men with moderately symptomatic
BPH showed significant improvements in IPSS (−5.4 vs.
–3.6 [p < 0.001]) in men who received FDC dutasteride
0.5 mg plus tamsulosin 0.4 mg versus tamsulosin
0.4 mg (initiated in men whose symptoms did not im-
prove with watchful waiting) [23].
FDC solifenacin 6 mg plus TOCAS 0.4 mg is the only
FDC α-blocker plus antimuscarinic approved for the
treatment of men with LUTS/BPH [12, 14] and the
inclusion of solifenacin within this FDC examined in our
study may have contributed to the main findings. Previ-
ously reported data from a large, retrospective observa-
tional cohort study of 8694 men with LUTS/BPH in the
UK showed that fewer patients discontinued (43.0% vs.
[mean] 53.0%) or switched treatment (15.3% vs. [mean]
22.0%) from solifenacin compared with most other anti-
muscarinics, and persisted on-treatment for longer
(median duration, 90 days vs. [range] 30–116 days) [16].
These findings are supported by further real-world data
in patients with OAB, suggesting that solifenacin pro-
vides greater treatment persistence compared with other
antimuscarinics (mean persistence 187 vs. 77–157 days;
persistence at 12 months, 35% vs. 14%–28%) [24]. The
reasons for improved persistence with solifenacin rela-
tive to other antimuscarinics are likely attributable to
the favourable efficacy and tolerability profile for solife-
nacin. A long-term open label study of solifenacin for up
to 1 year reported that 81% of patients completed
40 weeks of treatment and only 4.7% of patients discon-
tinued treatment due to AEs in patients with OAB [25].
A network meta-analysis of randomised controlled trials
conducted in adult patients with OAB showed that
solifenacin 5 mg/day provides similar or better efficacy,
and a lower or similar risk of dry mouth compared with
other common oral antimuscarinics [26]. Patients’
perceptions of symptom control/bother may also be a
factor in a decision to persist with or discontinue treatment.
Patients receiving solifenacin for the treatment of OAB
have reported significant improvements in health-related
quality of life and perceived bother compared with active
comparator treatment or placebo [27, 28]. Indeed, unmet
treatment expectations and/or tolerability are the primary
reasons for treatment discontinuation in up to 90% of
non-persistent patients [29]. In our study, although
time to discontinuation and persistence were greater
in patients receiving FDC or concomitant combinations
containing solifenacin versus other antimuscarinics, the
influence of solifenacin on switching could not be assesseddue to low numbers of men (N = 75) who met the switch-
ing criteria (i.e. replacing a discontinued index drug with
at least one new drug within 30 days of the discontinu-
ation date).
Baseline characteristics were well balanced at the
index date and few significant differences were ob-
served when the results for persistence were stratified
by age, polypharmacy and prescriber. These data sug-
gest that further study is needed to identify the key
drivers of persistence in men receiving combination
therapy for LUTS/BPH. In particular, it is hard to draw
conclusions regarding the true effects of polypharmacy
from the results, as men may have been receiving other
treatments for a number of different conditions, and
the definition of treatment-naïve men was only applied
for 6 months prior to the study commencing (as such,
the number of previous therapies for LUTS/BPH,
including prior receipt of combination therapy, and
the time since diagnosis could not be determined).
There was a trend (not statistically significant) for
greater persistence in men who received prescriptions
from urologists compared with GPs. This finding is
supported by recent evidence from a retrospective co-
hort study of 252 men with OAB, which reported that
persistence on treatment was higher among men re-
ceiving subspecialist supervision, compared with those
receiving treatment in internal medicine or general ur-
ology departments [30].
Strengths of this study include a large sample of
approximately 5000 men with LUTS/BPH and results
based on real-world data, using prescription records
from a representative sample of pharmacies and dispens-
ing GPs (corresponding to approximately 75% of retail
dispensing in the Netherlands). Although real-word data
were used, no in-depth clinical information was available
regarding diagnosis or reasons for stopping treatment
and this was a limitation. Other limitations of the data-
base were that no information was reported on whether
men received repeat prescriptions in other pharmacies
outside the panel, moved to another address or died
(although this was partly addressed by defining the post-
index period based on the last available information on
other medications). If a patient filed prescriptions at dif-
ferent pharmacies (i.e. one which was not included in
the panel), this resulted in missing medication history
and misclassification of patients. However, evidence sug-
gests that >90% of patients in the Netherlands are usu-
ally loyal to one pharmacy [31]. Also, no information
was available about whether drugs were taken correctly,
according to the treatment regimen; persistence and
adherence were calculated based on the recorded
duration of treatment and it was assumed that when a
patient was prescribed a medication then it was indeed
picked up and used by the patient (however, this
Drake et al. BMC Urology  (2017) 17:36 Page 10 of 12limitation is not restricted to retrospective analyses).
Therefore, persistence and adherence rates may have
been overestimated due to this assumption, although
this would have been equivalent in all subcohorts and
should not have influenced the comparative results.
Although a reasonable number of patients (>100) were
prescribed with tolterodine, oxybutynin and darifenacin,
solifenacin was the most commonly prescribed antimus-
carinic in the primary cohort of our study, and this may
have influenced the results of the antimuscarinic
subgroup analyses. Observational studies of treatment
persistence/adherence with antimuscarinic therapy
conducted in the UK and Canada also reported that
solifenacin was the most commonly prescribed medica-
tion for OAB [24, 32, 33]. However, the pattern of
prescriptions across the antimuscarinics was more
balanced in these studies, suggesting that the proportion
of patients prescribed with solifenacin in the current
study (74.4%) may be specific to the Netherlands.
Regarding α-blockers, tamsulosin is reported to be the most
commonly used for LUTS/BPH [16], but it should also be
noted that the impact of individual α-blockers used in com-
bination on persistence, adherence or switching were not
assessed in the same way as antimuscarinics in this study;
this could perhaps be evaluated in further studies.
Future qualitative studies could also explore the
rationale for treatment persistence/switching in LUTS/
BPH and the potential benefits which are derived from
improved persistence, particularly with regards to
efficacy and tolerability, and also healthcare resource
use and cost-effectiveness. In such analyses, it should
be taken into consideration that patients’ medication-
taking behaviour (i.e. persistence or adherence) can be
attributed to a number of factors, including side
effects experienced on-treatment [34, 35], the patient’s
beliefs, values [35] and perception of the severity of
their condition [34], and other behavioural or societal
factors [34].Conclusion
This study suggests that men with LUTS/BPH receiv-
ing α-blocker plus antimuscarinic combination therapy
as a FDC remain on treatment significantly longer and
have superior rates of persistence and adherence
compared with men receiving concomitant therapy of
an α-blocker plus antimuscarinic. These findings may
be useful for prescribers, as improved persistence on-
treatment may translate to improved outcomes for
men with LUTS/BPH. Further study is warranted to
assess the key drivers of persistence in men receiving
combination therapy for LUTS/BPH, and also to
establish the effects of such therapies on efficacy and
tolerability in this patient population.Additional files
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